CIPLA Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India; Belgium, & Surrey in the European Union; and Miami, Florida, in the United States. Stock price: CIPLA (NSE) Rs. 669.30 +8.65 (+1.31%)13 Feb, 11:21 am IST - Disclaimer

Founder: Khwaja Abdul Hamied Founded: 1935 Headquarters: Mumbai, IndiaPRODUCTS

Active Pharmaceutical Ingredients (API)

Cipla was among the first Indian companies to develop and manufacture Active Pharmaceutical Ingredients (APIs), the vital raw material for making the drug products. Thus helping lay the foundation for the pharmaceutical industry in India. Today, we manufacture over 200 generic APIs. This formidable portfolio covers a broad spectrum of therapeutic categories, reaching out to over 170 countries around the world. We meet stringent international standards of quality to deliver API. That’s the Cipla benchmark.

Products and services

Cipla manufactures a range of pharmaceutical and personal care products.[21] The company offers active pharmaceutical ingredients (APIs); and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health in various dosage forms. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices, such as dry powder inhalers, single-dose capsule and multi-dose dry powder inhalers, breath-actuated metered dose inhalers, non-static spacers, baby and infant masks, and nasal sprays. Further, it provides consulting, commissioning, plant engineering, and technical know-how transfer and support services.[21]

Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms.[22] Its key products include the following drugs - Escitalopram (anti-depressant), Lamivudine, Fluticasone propionate.[2]

HIV/AIDS medication

Cipla is the world's largest manufacturer of antiretroviral drugs [23] (ARVs) to fight HIV/AIDS, as measured by units produced and distributed. Roughly 40 percent of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs.[24][25]

From 1972 until 2005 Indian law did not allow product patents on drugs. As a result, Cipla was able to manufacture medicines which enjoyed patent monopoly in other countries.

Cipla also pioneered a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three ARVs (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents were held by different companies. Another

popular fixed-dose combination is produced under the name Duovir-N. This contains Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the most commonly prescribed anti-retroviral medication in the market,[26] and is a highly capable manufacturer in its own right. This innovation made ARVs far more accessible and easy-to-take for patients everywhere, but particularly in poor- and middle-income countries, where the vast majority of people on anti-retroviral therapy (ART) now take such combination pills.

Cipla was among the first companies to register AIDS drugs under the US relief program PEPFAR.[27] It has also been a major supplier of ARVs to the Clinton Foundation's HIV/AIDS Initiative, which has negotiated low-cost drug supplies for numerous developing countries.

Cipla has played an important role in fighting HIV/AIDS in Africa and other developing countries through its price offers to leading NGOs such as Doctors Without Borders and Oxfam, and with its keen participation in PEPFAR, the Global Fund, the Clinton Foundation's HIV/AIDS Initiative.[28]

CIPLAType Public

Traded   as

BSE: 500087NSE: CIPLABSE SENSEX ConstituentCNX Nifty Constituent

Industry PharmaceuticalsFounded 1935Founder Dr. K. A. HamiedHeadquarters Mumbai, Maharashtra, India

Area served Worldwide

Key peopleY. K. Hamied, ChairmanSubhanu Saxena (CEO)

Products Pharmaceuticals and diagnostics

Revenue104.83 billion

(US$1.6 billion) (2013-14)[1]

Operating income18.80 billion

(US$300 million) (2012-13)[1]

Net income13.89 billion

(US$220 million) (2013-14)[1]

Total assets109.68 billion

(US$1.7 billion) (2013-14)[1]

Total equity100.91 billion

(US$1.6 billion) (2013-14)[1]

Number of employees 22,036[2]